Drug intelligence / Profile preview

fexofenadine + pseudoephedrine

Development stage
Phase 4
Lead developer
Sanofi
Modality
Implantable Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
Administration
Oral
01

Overview

Fexofenadine + pseudoephedrine is a fixed-dose combination of two active ingredients used to treat symptoms associated with seasonal allergic rhinitis (hay fever), such as nasal congestion (stuffy nose), sneezing, runny nose, itchy or watery eyes, hives, skin rash, and itching. Fexofenadine is a second-generation antihistamine that works by selectively blocking peripheral histamine H1 receptors to reduce allergy symptoms. Pseudoephedrine is a sympathomimetic decongestant that acts primarily by stimulating alpha-adrenergic receptors in the respiratory tract mucosa to produce vasoconstriction and shrink swollen nasal passages. The combination provides both antihistaminic relief of allergy symptoms and decongestant action for nasal congestion[1][2][3][4][5].

Brand names
Allegra-DAllegra-D 12 HourAllegra-D12 HourAllegra-D-12 HourAllegra-D 24 HourAllegra-D24 HourAllegra-D-24 HourAllegra-D 12 Hour Allergy and CongestionAllegra-D12 Hour Allergy and CongestionAllegra-D-12 Hour Allergy and CongestionAllegra-D 24 Hour Allergy and CongestionAllegra-D24 Hour Allergy and CongestionAllegra-D-24 Hour Allergy and CongestionFexofenadine HCl-Pseudoephedrine 12 HourAllegra D OTC 24HR
Other names
Antihistamine and Nasal Decongestant
02

Targets

ADRA1 (Alpha-1 adrenergic receptor family)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on fexofenadine + pseudoephedrine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on fexofenadine + pseudoephedrine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call